Logo image of NLSN

NIELSEN HOLDINGS PLC (NLSN) Stock Fundamental Analysis

NYSE:NLSN - New York Stock Exchange, Inc. - GB00BWFY5505 - Common Stock - Currency: USD

27.98  +0.01 (+0.04%)

After market: 27.99 +0.01 (+0.04%)

Fundamental Rating

2

NLSN gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 82 industry peers in the Professional Services industry. NLSN may be in some trouble as it scores bad on both profitability and health. NLSN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

NLSN had positive earnings in the past year.
NLSN had a positive operating cash flow in the past year.
NLSN Yearly Net Income VS EBIT VS OCF VS FCFNLSN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 0 500M -500M 1B

1.2 Ratios

Industry RankSector Rank
ROA 4.86%
ROE 15.26%
ROIC 6.42%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NLSN Yearly ROA, ROE, ROICNLSN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 10 -10 20 -20

1.3 Margins

NLSN's Profit Margin has improved in the last couple of years.
In the last couple of years the Operating Margin of NLSN has grown nicely.
Industry RankSector Rank
OM 23.51%
PM (TTM) 14.99%
GM N/A
OM growth 3Y28.76%
OM growth 5Y6.33%
PM growth 3YN/A
PM growth 5Y43.28%
GM growth 3YN/A
GM growth 5YN/A
NLSN Yearly Profit, Operating, Gross MarginsNLSN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 20 40 60

More info and screens

2

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), NLSN is destroying value.
NLSN has more shares outstanding than it did 1 year ago.
NLSN has a better debt/assets ratio than last year.
NLSN Yearly Shares OutstandingNLSN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 100M 200M 300M
NLSN Yearly Total Debt VS Total AssetsNLSN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 5B 10B 15B

2.2 Solvency

NLSN has an Altman-Z score of 1.46. This is a bad value and indicates that NLSN is not financially healthy and even has some risk of bankruptcy.
The Debt to FCF ratio of NLSN is 8.68, which is on the high side as it means it would take NLSN, 8.68 years of fcf income to pay off all of its debts.
A Debt/Equity ratio of 1.61 is on the high side and indicates that NLSN has dependencies on debt financing.
Industry RankSector Rank
Debt/Equity 1.61
Debt/FCF 8.68
Altman-Z 1.46
ROIC/WACC0.88
WACC7.27%
NLSN Yearly LT Debt VS Equity VS FCFNLSN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2B 4B 6B 8B

2.3 Liquidity

A Current Ratio of 2.04 indicates that NLSN has no problem at all paying its short term obligations.
NLSN has a Quick Ratio of 2.04. This indicates that NLSN is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 2.04
Quick Ratio 2.04
NLSN Yearly Current Assets VS Current LiabilitesNLSN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 500M 1B 1.5B 2B 2.5B

More info and screens

3

3. Growth

3.1 Past

NLSN shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.15%.
NLSN shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -6.84% yearly.
The Revenue for NLSN has decreased by -28.72% in the past year. This is quite bad
NLSN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -11.12% yearly.
EPS 1Y (TTM)-2.15%
EPS 3Y23.97%
EPS 5Y-6.84%
EPS Q2Q%6.98%
Revenue 1Y (TTM)-28.72%
Revenue growth 3Y-18.71%
Revenue growth 5Y-11.12%
Sales Q2Q%2.44%

3.2 Future

The Earnings Per Share is expected to grow by 5.62% on average over the next years.
NLSN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.21% yearly.
EPS Next Y6.17%
EPS Next 2Y5.15%
EPS Next 3Y6.05%
EPS Next 5Y5.62%
Revenue Next Year2.38%
Revenue Next 2Y3.15%
Revenue Next 3Y3.41%
Revenue Next 5Y3.21%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
NLSN Yearly Revenue VS EstimatesNLSN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2B 4B 6B
NLSN Yearly EPS VS EstimatesNLSN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.5 1 1.5 2 2.5

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 15.37 indicates a correct valuation of NLSN.
The average S&P500 Price/Earnings ratio is at 27.69. NLSN is valued slightly cheaper when compared to this.
Based on the Price/Forward Earnings ratio of 13.98, the valuation of NLSN can be described as correct.
Compared to an average S&P500 Price/Forward Earnings ratio of 37.36, NLSN is valued rather cheaply.
Industry RankSector Rank
PE 15.37
Fwd PE 13.98
NLSN Price Earnings VS Forward Price EarningsNLSN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF 15.56
EV/EBITDA 11.18
NLSN Per share dataNLSN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10 -15

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates NLSN does not grow enough to justify the current Price/Earnings ratio.
PEG (NY)2.49
PEG (5Y)N/A
EPS Next 2Y5.15%
EPS Next 3Y6.05%

More info and screens

3

5. Dividend

5.1 Amount

With a yearly dividend of 0.86%, NLSN is not a good candidate for dividend investing.
With a Dividend Yield of 0.86, NLSN pays less dividend than the S&P500 average, which is at 2.34.
Industry RankSector Rank
Dividend Yield 0.86%

5.2 History

The dividend of NLSN decreases each year by -44.32%.
NLSN has paid a dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)-44.32%
Div Incr YearsN/A
Div Non Decr YearsN/A
NLSN Yearly Dividends per shareNLSN Yearly Dividends per shareYearly Dividends per share 2015 2016 2017 2018 2019 2020 2021 2022 0.2 0.4 0.6 0.8 1

5.3 Sustainability

16.23% of the earnings are spent on dividend by NLSN. This is a low number and sustainable payout ratio.
DP16.23%
EPS Next 2Y5.15%
EPS Next 3Y6.05%
NLSN Yearly Income VS Free CF VS DividendNLSN Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 0 500M -500M
NLSN Dividend Payout.NLSN Dividend Payout, showing the Payout Ratio.NLSN Dividend Payout.PayoutRetained Earnings

More info and screens

NIELSEN HOLDINGS PLC

NYSE:NLSN (10/11/2022, 8:25:24 PM)

After market: 27.99 +0.01 (+0.04%)

27.98

+0.01 (+0.04%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCommercial & Professional Services
GICS IndustryProfessional Services
Earnings (Last)07-27 2022-07-27/bmo
Earnings (Next)11-04 2022-11-04/bmo
Inst Owners0.01%
Inst Owner Change0%
Ins Owners10.9%
Ins Owner Change0%
Market Cap10.07B
Analysts71.43
Price Target28.56 (2.07%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.86%
Yearly Dividend0.24
Dividend Growth(5Y)-44.32%
DP16.23%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.58%
Min EPS beat(2)6.72%
Max EPS beat(2)10.45%
EPS beat(4)4
Avg EPS beat(4)16.96%
Min EPS beat(4)6.72%
Max EPS beat(4)26.96%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.28%
Min Revenue beat(2)-2.35%
Max Revenue beat(2)-2.21%
Revenue beat(4)0
Avg Revenue beat(4)-1.93%
Min Revenue beat(4)-2.41%
Max Revenue beat(4)-0.73%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 15.37
Fwd PE 13.98
P/S 2.85
P/FCF 15.56
P/OCF 10.25
P/B 2.9
P/tB N/A
EV/EBITDA 11.18
EPS(TTM)1.82
EY6.5%
EPS(NY)2
Fwd EY7.15%
FCF(TTM)1.8
FCFY6.43%
OCF(TTM)2.73
OCFY9.75%
SpS9.82
BVpS9.65
TBVpS-15.24
PEG (NY)2.49
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 4.86%
ROE 15.26%
ROCE N/A
ROIC 6.42%
ROICexc N/A
ROICexgc 51.61%
OM 23.51%
PM (TTM) 14.99%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y4.08%
ROICexcg growth 5Y-0.34%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y28.76%
OM growth 5Y6.33%
PM growth 3YN/A
PM growth 5Y43.28%
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 1.61
Debt/FCF 8.68
Debt/EBITDA N/A
Cap/Depr 64.92%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality 122.08%
Current Ratio 2.04
Quick Ratio 2.04
Altman-Z 1.46
F-Score6
WACC7.27%
ROIC/WACC0.88
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2.15%
EPS 3Y23.97%
EPS 5Y-6.84%
EPS Q2Q%6.98%
EPS Next Y6.17%
EPS Next 2Y5.15%
EPS Next 3Y6.05%
EPS Next 5Y5.62%
Revenue 1Y (TTM)-28.72%
Revenue growth 3Y-18.71%
Revenue growth 5Y-11.12%
Sales Q2Q%2.44%
Revenue Next Year2.38%
Revenue Next 2Y3.15%
Revenue Next 3Y3.41%
Revenue Next 5Y3.21%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y6.59%
FCF growth 3Y-15.47%
FCF growth 5Y-17.74%
OCF growth 1Y-12.94%
OCF growth 3Y-14.3%
OCF growth 5Y-12.47%